Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

Condition(s) studied

Investigational drug(s) / intervention(s)

Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients: Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients

Standard nutritional intervention was administered as a positive control to validate experimental efficacy.: Standard nutritional intervention was administered as a positive control to validate experimental efficacy.

Administration of placebo as a negative control to validate experimental efficacy: Administration of placebo as a negative control to validate experimental efficacy

Study summary

Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.

Eligibility

Primary outcome measure(s)

• Change in skeletal muscle index (SMI, cm²/m²) — Baseline to 12 months (assessed at 1, 3, 6, and 12 months)
  Skeletal muscle index (SMI) is calculated from cross-sectional CT images at the third lumbar vertebra (L3) level and normalized by height (cm²/m²).

Trial sites (1)

More China Medical University, China trials in China

Other trials for the same condition